Nektar Therapeutics (NKTR)
NASDAQ$0.8968
Market Cap
$165.42M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
732 of 924
Rank in Industry
416 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
NKTR Insider Trading Activity
NKTR Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $511,901 | 19 | 100 |
Related Transactions
| CHESS ROBERT | director | 0 | $0 | 1 | $23,400 | $-23,400 |
| Wilson Mark Andrew | Chief Legal Officer | 0 | $0 | 6 | $80,610 | $-80,610 |
| Zalevsky Jonathan | Chief R&D Officer | 0 | $0 | 5 | $87,974 | $-87,974 |
| Deep Track Capital, LP | 10 percent owner | 0 | $0 | 1 | $99,630 | $-99,630 |
| ROBIN HOWARD W | President & CEO | 0 | $0 | 6 | $220,287 | $-220,287 |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell …
Insider Activity of Nektar Therapeutics
Over the last 12 months, insiders at Nektar Therapeutics have bought $0 and sold $511,901 worth of Nektar Therapeutics stock.
On average, over the past 5 years, insiders at Nektar Therapeutics have bought $0 and sold $5.14M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $259,200 was made by Doberstein Stephen K (SVP & Chief Scientific Officer) on 2019‑09‑05.
List of Insider Buy and Sell Transactions, Nektar Therapeutics
| 2025-02-19 | Sale | ROBIN HOWARD W | President & CEO | 23,774 0.0123% | $1.01 | $24,012 | -15.92% | |
| 2025-02-19 | Sale | Wilson Mark Andrew | Chief Legal Officer | 11,040 0.0057% | $1.01 | $11,150 | -15.92% | |
| 2025-02-19 | Sale | Zalevsky Jonathan | Chief R&D Officer | 10,300 0.0053% | $1.01 | $10,403 | -15.92% | |
| 2024-12-24 | Sale | Wilson Mark Andrew | Chief Legal Officer | 16,560 0.0088% | $0.89 | $14,738 | -3.28% | |
| 2024-12-23 | Sale | Wilson Mark Andrew | Chief Legal Officer | 33,402 0.018% | $0.90 | $30,062 | -2.12% | |
| 2024-12-19 | Sale | Zalevsky Jonathan | Chief R&D Officer | 51,115 0.027% | $0.94 | $48,048 | -5.60% | |
| 2024-12-18 | Sale | ROBIN HOWARD W | President & CEO | 85,035 0.0497% | $0.99 | $84,185 | -3.61% | |
| 2024-12-17 | Sale | ROBIN HOWARD W | President & CEO | 46,995 0.0255% | $1.01 | $47,465 | -12.57% | |
| 2024-11-19 | Sale | ROBIN HOWARD W | President & CEO | 16,278 0.0087% | $1.01 | $16,441 | -10.87% | |
| 2024-11-19 | Sale | Zalevsky Jonathan | Chief R&D Officer | 7,785 0.0042% | $1.01 | $7,863 | -10.87% | |
| 2024-11-19 | Sale | Wilson Mark Andrew | Chief Legal Officer | 6,407 0.0034% | $1.01 | $6,471 | -10.87% | |
| 2024-08-19 | Sale | ROBIN HOWARD W | President & CEO | 14,881 0.0078% | $1.28 | $19,048 | -19.55% | |
| 2024-08-19 | Sale | Zalevsky Jonathan | Chief R&D Officer | 6,866 0.0036% | $1.28 | $8,788 | -19.55% | |
| 2024-08-19 | Sale | Wilson Mark Andrew | Chief Legal Officer | 5,651 0.003% | $1.28 | $7,233 | -19.55% | |
| 2024-06-14 | Sale | CHESS ROBERT | director | 19,500 0.0101% | $1.20 | $23,400 | 0.00% | |
| 2024-05-17 | Sale | ROBIN HOWARD W | President & CEO | 16,650 0.0087% | $1.75 | $29,138 | -32.95% | |
| 2024-05-17 | Sale | Zalevsky Jonathan | Chief R&D Officer | 7,355 0.0039% | $1.75 | $12,871 | -32.95% | |
| 2024-05-17 | Sale | Wilson Mark Andrew | Chief Legal Officer | 6,260 0.0033% | $1.75 | $10,955 | -32.95% | |
| 2024-05-10 | Sale | Deep Track Capital, LP | 10 percent owner | 56,000 0.0308% | $1.78 | $99,630 | -32.39% | |
| 2024-02-20 | Sale | ROBIN HOWARD W | President & CEO | 20,033 0.0107% | $0.68 | $13,622 | +82.34% |
Total: 454
*Gray background shows transactions not older than one year
Insider Historical Profitability
6.73%
| ROBIN HOWARD W | President & CEO | 1086901 0.5892% | $974,732.82 | 1 | 80 | <0.0001% |
| WHITFIELD ROY A | director | 216250 0.1172% | $193,933.00 | 3 | 2 | +51.06% |
| GREER R SCOTT | director | 176574 0.0957% | $158,351.56 | 1 | 5 | +42.48% |
| Doberstein Stephen K | SVP & Chief Scientific Officer | 107668 0.0584% | $96,556.66 | 1 | 20 | +17.27% |
| WINGER DENNIS L | director | 42750 0.0232% | $38,338.20 | 1 | 4 | +8.33% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$2,924,567 | 72 | -4.87% | $157.74M | |
$613,304,943 | 46 | 11.85% | $191.55M | |
$79,019,806 | 27 | 7.24% | $165.26M | |
$6,915,275 | 21 | -32.61% | $158.47M | |
$2,484,989 | 17 | -17.86% | $156.9M |
NKTR Institutional Investors: Active Positions
| Increased Positions | 70 | +49.65% | 22M | +15.73% |
| Decreased Positions | 51 | -36.17% | 30M | -21.32% |
| New Positions | 21 | New | 5M | New |
| Sold Out Positions | 16 | Sold Out | 2M | Sold Out |
| Total Postitions | 160 | +13.48% | 133M | -5.59% |
NKTR Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $13,517.00 | 8.74% | 16.09M | +122,236 | +0.77% | 2024-12-31 |
| Vanguard Group Inc | $10,356.00 | 6.7% | 12.33M | -792,771 | -6.04% | 2024-12-31 |
| Samlyn Capital, Llc | $8,120.00 | 5.25% | 9.67M | +467,097 | +5.08% | 2024-12-31 |
| Nantahala Capital Management, Llc | $6,560.00 | 4.25% | 7.81M | +4M | +90.02% | 2024-12-31 |
| Acadian Asset Management Llc | $6,049.00 | 3.91% | 7.2M | +2M | +27.34% | 2024-12-31 |
| Eventide Asset Management, Llc | $5,586.00 | 3.61% | 6.65M | -3M | -29.25% | 2024-12-31 |
| Primecap Management Co/Ca/ | $4,654.00 | 3.01% | 5.54M | -372,067 | -6.29% | 2024-12-31 |
| Woodline Partners Lp | $4,179.00 | 2.7% | 4.97M | +3M | +187.27% | 2024-12-31 |
| Millennium Management Llc | $3,801.00 | 2.46% | 4.52M | -536,773 | -10.61% | 2024-12-31 |
| Tcg Crossover Management, Llc | $3,360.00 | 2.17% | 4M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.